Jefferies backs Lupin, Zydus, and Biocon amid shifting US pharma market shares. Discover why these stocks are set to shine.

Boehringer’s lung drug Spiriva, approved for chronic obstructive pulmonary disease (COPD) and asthma, generated net sales of 2.4 billion euros, down 11.4% compared with last year, which the ...

As the EU patent expires on its flagship respiratory diseases product, Spiriva, Boehringer Ingelheim is looking to newer diabetes and respiratory drugs under the leadership of a new CEO.

Objective: To review available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of cilomilast, a selective phosphodiesterase-4 (PDE4) inhibitor ...

The relationship between chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) is important, significant and overlapping in nature. This review will analyze the relationship ...